Author
@fwpharma fwpharma
Biopharma trade-press feed relaying FDA, clinical, M&A and earnings news in real time
FirstWord Pharma's account broadcasts comprehensive, first-p
trader score
+0.22
hit rate
40%
mean α
+0.11%
signals 14d
34
Grade = how their written analysis reads (A best). Trader score = how their last-20 timestamped calls performed vs SPY.
Their picks, scored
Across their last 20 scored bets: 40% hit rate, +0.11% mean alpha, trader score +0.22. Their last-14d mentions, direction-adjusted, have moved +3.7% since posting (mean over 18 mentions with price data).
Recent signals15receipts included
| date (PT) | ticker | author | sent | what they said | since then | receipt |
|---|---|---|---|---|---|---|
| 2026-07-02 | AZN | @fwpharma | +0.20 | AstraZeneca signed a near $1.8B deal with CSPC for renal disease drugs. | — | tweet ↗ |
| 2026-07-02 | RHHBY | @fwpharma | +0.45 | Roche's divarasib beat KRAS G12C rivals in a late-stage NSCLC study. | — | tweet ↗ |
| 2026-07-01 | CANF | @fwpharma | +0.45 | Can-Fite posted positive mid-stage data for an oral pancreatic cancer drug. | · | tweet ↗ |
| 2026-07-01 | ALZCUR | @fwpharma | +0.40 | AlzeCure surged on another backloaded Alzheimer's drug development deal. | · | tweet ↗ |
| 2026-07-01 | IPSEY | @fwpharma | -0.10 | Ipsen struck a second buyout in a week with a €700M Memo acquisition. | · | tweet ↗ |
| 2026-06-29 | EVMN | @fwpharma | -0.60 | Evommune oral drug failed a mid-stage urticaria study. | · | tweet ↗ |
| 2026-06-29 | AMGN | @fwpharma | -0.10 | Viridian thyroid eye disease drug won FDA approval, competing with Amgen Tepezza. | +3.8% | tweet ↗ |
| 2026-06-29 | VRDN | @fwpharma | +0.50 | Viridian thyroid eye disease drug won FDA approval, competing with Amgen Tepezza. | +3.2% | tweet ↗ |
| 2026-06-29 | ZYME | @fwpharma | -0.10 | Zymeworks buying Theravance for $929M. | · | tweet ↗ |
| 2026-06-29 | TBPH | @fwpharma | +0.50 | Zymeworks buying Theravance for $929M. | · | tweet ↗ |
| 2026-06-29 | IPSEY | @fwpharma | -0.10 | Ipsen to pay $1.75B for Kartos and its blood cancer asset. | · | tweet ↗ |
| 2026-06-26 | AMGN | @fwpharma | -0.50 | CHMP recommendation to revoke approval of Amgen's Tavneos. | +4.4% | tweet ↗ |
| 2026-06-26 | SNY | @fwpharma | -0.30 | Sanofi faces formal EU probe over campaign allegedly disparaging rival flu shot. | +0.5% | tweet ↗ |
| 2026-06-24 | NVS | @fwpharma | +0.25 | Novartis taps Antares in $1.9B oncology deal. | +4.4% | tweet ↗ |
| 2026-06-24 | LLY | @fwpharma | +0.25 | Lilly enters $1.9B R&D alliance with Abbisko. | +8.7% | tweet ↗ |
Grade is our human read-worthiness rating; trader score is a rolling 20-bet hit-rate/alpha composite — different things, often disagreeing. “Since then” is direction-unaware in the table; the summary line above adjusts for which way they leaned.